Is 5-MAPB the closest chemical successor to the legendary experience of MDMA?

History · Published 3 October 2026 Swipe more like this →

In short: Known as MDMA 2.0, 5-MAPB is a potent designer drug that mimics the entactogenic effects of ecstasy while promising a smoother comedown. First synthesized in 2009, this benzofuran analogue has sparked intense debate over its safety, legal status, and potential as a future psychiatric medicine.

5-MAPB, or 5-(N-methyl-2-aminopropyl)benzofuran, emerged as a novel designer drug around 2013, with its synthesis first reported in 2009 by Ezekiel Golan. Chemically, it is a structural analogue of MDMA, differing by the replacement of one oxygen atom in the benzodioxole ring with a carbon atom. This modification results in a substance that is roughly two to three times more potent than MDMA, with a duration of effect lasting five to six hours—about twice as long as its predecessor.

The drug functions as a serotonin–norepinephrine–dopamine releasing agent, similar to MDMA, but with distinct receptor activity. Matthew Baggott has noted that 5-MAPB is the closest-known analogue to MDMA in terms of its subjective effects, often described as purely entactogenic. Unlike MDMA, which is known for its stimulating properties, 5-MAPB is reported to be less stimulating and is frequently used in the so-called Borax combo, a mixture designed to more closely replicate the full MDMA experience.

Despite its reputation as a potentially less neurotoxic alternative, the reality is complex. While 5-MAPB does not form the alpha-methyldopamine metabolite associated with MDMA's toxicity, studies in rodents have shown it can still act as a dose-dependent serotonergic neurotoxin. Furthermore, its legal status remains a global patchwork: it was banned in the UK in 2014 and in China by 2015, while in the United States, it exists in a legal gray area, often sold as a recreational substance despite potential risks under the Federal Analogue Act.

The future of 5-MAPB may lie in clinical settings rather than recreational markets. The company Tactogen has patented the compound for potential use in treating psychiatric disorders. As research continues, the scientific community remains cautious, balancing the drug's unique pharmacological profile against documented cases of hospitalization and death, highlighting the thin line between therapeutic promise and the dangers of designer substances.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• 2C-B, Shulgin's 1974 invention, is now tested head-to-head against MDMA and psilocybin
• Beyond the rave, can MDMA rewire the brain to heal severe trauma?
• Is this synthetic tryptamine truly indistinguishable from the active compound in magic mushrooms?
• The dragonfly drug with a six-hour delay and deadly potency
• The first blockbuster psychotropic drug that defined 1950s American culture and then vanished
• The Sultan who built schools to prevent a revolution, only to train his successors
• How a British oil dispute triggered a CIA-led coup in 1953 Iran
• Is the British monarchy losing its grip on the public imagination after forty years?
• The 1860 election: A fractured nation chooses a president with less than 40 percent support
• Were the Achaeans of Homer a real historical power or a literary invention?
• The Alawi Sultanate: How a Sharifian Dynasty Unified Morocco and Navigated Global Powers
• The Alawites: From a Marginalized Sect to the Architects of Modern Syrian Power

More in Empires & civilisations · More in History · Latest · A–Z · All topics